Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono/Seikagaku’s Novel Osteoarthritis Drug Delivers in Japan PIII for Knee Pain
June 12, 2020
- 100 mg Version of Vimpat IV Infusion Now Available in Japan: UCB
June 12, 2020
- Shonan iPark to Launch VC Consortium
June 12, 2020
- Investigator-Initiated Study to Be Launched for Telomelysin/Radiotherapy in US: Oncolys
June 11, 2020
- Sanofi Rolls Out Soliqua Injection SoloStar for Type 2 Diabetes in Japan
June 10, 2020
- Xofluza Shows Favorable Results in Patients at High Risk of Flu Complications in Global PIII: Shionogi
June 10, 2020
- Japan Ethical Drug Sales Up 2.6% in April: Crecon
June 10, 2020
- Kyowa Kirin’s Hyperphosphatemia Treatment Tenapanor Hits Primary Goal in Japan PII
June 10, 2020
- Jiangsu Hengrui to Return Telomelysin’s China Rights to Oncolys
June 10, 2020
- Nippon Shinyaku’s DMD Drug Gets Orphan Status in Europe
June 9, 2020
- Evrenzo Shows Non-Inferiority to Nesp in Non-Dialysis CKD Patients
June 9, 2020
- Takhzyro Shows Sustained Effect in Staving Off HAE Attacks
June 9, 2020
- Big 3 Generic Firms Log 5.9% Sales Increase in FY2019, with Contraction in Overseas Business: Jiho Tally
June 9, 2020
- Bayer HIF-PH Inhibitor Molidustat Filed in Japan in Q1
June 9, 2020
- Japan Team to Develop Nafamostat Inhaler Formulation for COVID-19
June 9, 2020
- Fujifilm’s Avigan COVID-19 Trial Might Continue into July
June 9, 2020
- Chugai Files FoundationOne as Lynparza CDx for mCRPC
June 8, 2020
- Meiji Pharma Jettisons Nail Ringworm Med ME1111
June 8, 2020
- Opdivo Gets Taiwan Nod for Second-Line Esophageal Cancer
June 8, 2020
- Ono Kicks Off Japan Clinical Study for Pancreatitis Med Foipan for COVID-19
June 8, 2020
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…